Navigation Links
Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
Date:3/4/2010

LAWRENCEVILLE, N.J., March 4 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that in an independent survey of U.S. ophthalmologists by Frost & Sullivan, Timoptic® was rated the leading brand name of beta blockers for glaucoma. Timoptic received Frost & Sullivan's 2010 Best Practices Award as the "Best Brand Name of Beta Blockers for Glaucoma," based on its Brand Perception Index (BPI) score, reflecting strong brand reputation, recognition and customer loyalty.

Provided by Aton Pharma, Timoptic (timolol maleate) is a non-selective, beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.  

Frost & Sullivan surveyed 150 U.S. ophthalmologists using a web-based survey methodology during November 2009. In the survey, 50 percent of ophthalmologists ranked Timoptic as the #1 brand name of beta blockers – overwhelmingly above the nearest competitor. Overall, 54 percent of U.S. ophthalmologists surveyed use Timoptic as their primary beta blocker product for the treatment of glaucoma. Among those who use it, nearly all report Timoptic as one of the top three beta blockers for glaucoma.

"We are pleased that ophthalmologists recognize the Timoptic product line," stated Michael G. Wells, Chief Executive Officer of Aton Pharma.

"Based on its positive, strong brand reputation and high percentage of loyal ophthalmologist customers, Timoptic's Brand Perception Index (BPI) score qualified it as the 'Best Brand Name of Beta Blockers for Glaucoma'," commented Tonya M. Fowler, Frost & Sullivan's Global Director of Customer Research.

Aton CEO Wells added that the company is particularly pleased to build on Timoptic's reputation by providing Timoptic in Ocudose®, the only preservative-free medication for glaucoma available in the U.S. "With preservative-free Timoptic in Ocudose, Aton is able to enhance its mission of providing medically essential therapeutics that serve a critical role in the practice of medicine."

A preservative-free beta blocker is an important option for many glaucoma patients, who must use medication for long periods of time. Preservatives in glaucoma medications have been noted in the medical literature to cause some patients discomfort upon installation and may have toxic effects, compromising tear film stability and causing damage to the cornea and conjunctiva. This is a particular concern for those who already have dry eye, are at increased risk for ocular surface disease or are taking more than one prescribed medication for glaucoma.(1-3)

In an additional survey of ophthalmologists in March 2009 sponsored by Aton Pharma, virtually all (97%) believed preservative-free glaucoma medications may enhance the ocular comfort of glaucoma patients, while 86 percent believed that preservative-free glaucoma medications may enhance patient quality of life.  

About Timoptic

The U.S. Timoptic product line includes Timoptic (timolol maleate) Ophthalmic Solution, Timoptic (timolol maleate ophthalmic solution) in Ocudose® (sterile ophthalmic unit dose dispenser) and Timoptic-XE (timolol maleate ophthalmic gel forming solution) Ophthalmic. Timoptic in Ocudose is the only preservative-free medication for glaucoma available in the U.S. and aligns with Aton's strategy of providing unique, medically essential products.

Timoptic is indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Timoptic is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration. The most frequent adverse events have been burning and stinging upon installation. For more information, see www.ocudose.com.

About Frost & Sullivan Best Practices Awards

Frost & Sullivan Best Practice Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Customer Research analysts conduct the survey research to identify best practices in the industry.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

(1.) Baudouin C. The ocular surface in glaucoma, Cornea, Volume 28, Number 9, Suppl. 1, October 2009.

(2.) de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232: 221–224.

(3.) Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.

SOURCE Aton Pharma, Inc.

Back to top

RELATED LINKS
http://www.ocudose.com
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
3. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
4. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
5. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
6. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
7. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
8. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough
11. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... VENICE, Fla. , Feb. 5, 2016 /PRNewswire/ ... Centers , is the first of its kind ... of undesired tattoos through advanced laser treatment. The ... Florida,s Suncoast by storm with ... video consultations, and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... the election of Patrick McDermott as Chairman of the National Board of Directors. Mr. ... as Chairman of the Board,” stated Leslie A. Chambers , APDA President and ...
(Date:2/5/2016)... San Francisco, CA (PRWEB) , ... February 05, ... ... dentist and founder of CitiDent, announces that it is now welcoming ... by Dr. Cheng, CitiDent offers a complete range of oral health care, including ...
(Date:2/5/2016)... ... 2016 , ... Health and wellness is a topic that should concern all ... are experiencing an illness. Migraines are a severe form of a headache and often ... not wish the pain on their worst enemy, the feeling can last for many ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):